Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

$0.4 million increase in these unallocated research and development costs is spread out across personnel costs (increased headcount initiated last year, particularly with respect to non-clinical work in the celgosivir program), patent costs (advancement of MX-3253 patent applications) and other costs (higher level of activity in both the MX-3253 and MX-2401 programs).

We anticipate that we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis. We are currently focusing our resources on advancing the development of our non-partnered programs: celgosivir and MX-2401.

General and Corporate Expenses

General and corporate expenses in Q1/08 were $1.0 million (Q1/07: $0.8 million). Personnel costs were $0.5 million in Q1/08 (Q1/07: $0.5 million). The approximate $0.2 million increase in general and corporate costs in Q1/08 compared with Q1/07 is principally due to: (i) contract personnel in the Finance department engaged for internal controls, implementation of new accounting software and year end work; and (ii) greater legal and accounting costs.

Amortization

Amortization expense for equipment was approximately $0.1 million for Q1/08 (Q1/07: $0.1 million).

Amortization expense for intangible assets was approximately $0.1 million for Q1/08 (Q1/07: $0.2 million).

Other Income and Expenses

Interest income was $0.1 million for Q1/08 (Q1/07: $0.1 million).

Accretion expense related to the convertible royalty participation units for Q1/08 was $0.4 million (Q1/07: $0.3 million). This accretion expense is a non-cash expense resulting from accreting the liability component of the convertible royalty participation units to the maximum royalties payable of $29.5 million (will be reduced for actual royalties paid, any units converted into common shares and should the estimate of royalties payable decline below $29.5 million) over the estimated royalty payment te
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... BioPlus Specialty Pharmacy (BioPlus) announces the ... President of Managed Care. In this role, Damm will ... the nation’s leading specialty pharmacies. , Damm, who is ... specialty pharmacy and biotech experience to his new position ... Pharmaceuticals, and Pfizer. Prior to working in Healthcare Damm ...
(Date:3/5/2015)... 05, 2015 Research and Markets ( ... "Mature Biotech Outlook 2015: New Therapy Ventures Pave the ... All biotech companies - Gilead (GILD), Amgen ... year, have given a positive return and hence increased ... able to select therapy/niche indication where the high treatment ...
(Date:3/4/2015)... 2015 PDL BioPharma, Inc. (PDL) (NASDAQ: ... the: , 3.75% Convertible Senior Notes due May ... stock per $1,000 principal amount or approximately $5.72 per share, ... the note is adjusted in connection with the regular quarterly ... all stockholders who own shares of PDL on March 5, 2015, ...
(Date:3/4/2015)... , Mar. 04, 2015 Research and ... the addition of Jain PharmaBiotech,s new report ... their offering. This report follows ... characteristic that can be objectively measured and evaluated ... processes as well as pharmacological responses to a ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3
... of partner clinics, fits dozens ... ... /PRNewswire/ - Touch,Bionics, developer of the world,s first commercially available bionic ... Currently basing U.S. operations out of Boston, MA, this announcement,follows the ...
... Cynosure, Inc.,(Nasdaq: CYNO ), a leading developer ... treatment systems, today announced that the company,will host ... on Tuesday,February 12, 2008 at 9:00 a.m. ET., ... Officer Michael Davin and,Executive Vice President and Chief ...
... Ga. and RESEARCH TRIANGLE PARK, N.C., Jan. 29 ,Merial ... signed an,agreement under which Merial will screen a Chimerix ... of this agreement, Merial has an,option to negotiate a ... use., "This collaboration with Chimerix provides us with ...
Cached Biology Technology:Touch Bionics expands U.S. presence to meet demand for i-LIMB Hand 2Touch Bionics expands U.S. presence to meet demand for i-LIMB Hand 3Touch Bionics expands U.S. presence to meet demand for i-LIMB Hand 4Cynosure to Announce Fourth-Quarter and Full Year 2007 Financial Results on February 12 2Merial to Screen Chimerix' Chemical Library for Animal Health Drug Leads 2
(Date:2/24/2015)... This report analyzes the worldwide markets for Face and ... and Voice Biometrics. The report provides separate comprehensive analytics for the ... Europe , Asia-Pacific , ... and Latin America . Annual estimates and forecasts ... historic analysis is provided for these markets. Market data and analytics ...
(Date:2/23/2015)... OXFORD, Conn. , Feb. 23, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... it has filed provisional patent 62114357 for ... With this patent, NXT-ID introduces a new groundbreaking payment ... and the payment account may only be accessed if ...
(Date:2/18/2015)... (NASDAQ: CPHD ) today announced that its executives ... to participate via webcast. , Cowen and Company Health ... 3, 2015 at 11.20 a.m. Eastern Time , Raymond ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern Time ... these events, please visit Cepheid,s website at http://ir.cepheid.com ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2
... Researchers at Huntsman Cancer Institute (HCI) at the University ... often deadly bone cancer that typically afflicts children and young ... tumors with high levels of a protein known as GSTM4, ... published online today in the journal Oncogene . ...
... of Oceanography at UC San Diego and their colleagues ... structure of a naturally produced, ocean-based compound that is ... cells. The findings are reported in the Aug. ... Biology by principal co-investigators William Gerwick, professor of ...
... (August 28, 2009)The American Phytopathological Society (APS) is proud ... Scientist, is the recipient of the 2009 Plant Pathology ... Green Menace," published in the March 13, 2008, issue ... Green Menace," Callaway discussed the citrus disease huanglongbinga bacterial ...
Cached Biology News:New hope for deadly childhood bone cancer 2Marine biomedicine researchers decode structure of promising sea compound 2Ewen Callaway named 2009 APS Plant Pathology Journalism awardee 2
Anti-MMP-19 (RASI), carboxy terminal region; rabbit host...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Rabbit polyclonal to ATF4 (phospho S245) ( Abpromise for all tested applications). Antigen: Synthetic phosphopeptide derived from human ATF4 around the phosphorylation site of Serine 245. En...
Evolutionarily conserved signaling intermediate in Toll pathway...
Biology Products: